Ocumension Therapeutics (HK:1477) has released an update.
Ocumension Therapeutics has announced an extraordinary general meeting (EGM) to be held on October 16, 2024, in Shanghai, to discuss and potentially approve a series of ordinary resolutions related to a significant transaction with Alcon Pharma. Among the key topics are the ratification of the Transaction Documents, the issuance of Consideration Shares for an acquisition and in-licensing, and the approval of proposed annual caps for transactions. Shareholders are entitled to appoint proxies to vote on their behalf for the resolutions that will shape the company’s strategic direction.
For further insights into HK:1477 stock, check out TipRanks’ Stock Analysis page.
